Steven D Nathan,1 Ulrich Costabel,2 Lisa H Lancaster,3 Tamera J Corte,4 Hilario Nunes,5 Birgit Schinzel,6 Manuel Quaresma,6 Athol U Wells7
1Inova Fairfax Hospital, Falls Church, Virginia, USA; 2Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany; 3Vanderbilt University Medical Center, Nashville, Tennessee, USA; 4Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia and University of Sydney, New South Wales, Australia; 5Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France; 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 7National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK
Introduction
- Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterized by decline in lung function and high mortality.1
- Acute exacerbations and hospitalizations are common features of the clinical course of IPF.2,3